Kansai International Airport’s Populous Redesigned Terminal 1 Opens Ahead of World Expo 2025
Kansai Airports and global design firm Populous have been working for more than seven years to completely reimagine the airport’s floor plan, bringing a new level of efficiency and experience for travellers to Japan’s west.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250331282189/en/
KANSAI INTERNATIONAL AIRPORT'S POPULOUS REDESIGNED TERMINAL 1 OPENS AHEAD OF WORLD EXPO 2025. The final phase of the refurbished Kansai International Airport (KIX) Terminal 1 has opened on 27 March 2025 to accommodate the millions of passengers expected to pass through the iconic building to attend World Expo in Osaka. Kansai Airports and global design firm Populous have been working for more than seven years to completely reimagine the airport's floor plan, bringing a new level of efficiency and experience for travellers to Japan's west.
Populous Senior Principal and Director, Brett Wightman, said the original Kansai International Airport (KIX) Terminal 1 wanted to make the best possible use of the existing infrastructure and maximize commercial return for Kansai Airports.
“Working closely with the facility operators, key stakeholders and end users, as well as expert retail and planning consultants, we have been able to craft a design that is built upon operational functionality, passenger convenience, accessibility and sustainability, while delivering innovative solutions that create an authentic and experiential environment with a clearly defined spirit of place,” Mr Wightman said.
The new Terminal 1 includes a 60% increase in the size of the international departure lounge and retail offerings, the introduction of innovative retail layouts based on passenger experiences, and the creation of a seamless processing experience.
PHASED RENOVATION TO ALLOW FOR CONTINUED OPERATIONS
Populous led the architecture and interior design of the redevelopment, as well overseeing the project throughout construction.
Mr Wightman said, importantly, the design considered operational functionality during renovation.
The project has been completed in four phases to allow for continued operations of the airport, which is expected to accommodate more than 40 million passengers a year from 2025 and almost double international capacity.
In October 2022, KIX opened the new Phase 1 domestic area followed by the new international area. Phase 2 of the project was completed in December 2023, and included 6,650 square meters of additional airside retail outlets, 1,130 square meters of food and beverage space and a new centralized immigration area.
The Populous team and Kansai Airports completed Phase 3 on March 27, 2025, allowing the consolidation and extension of the security screening area to be ready before World Expo 2025 begins in April in Osaka.
PHASE 3 – INTERNATIONAL SECURITY CHECKPOINT OPENS 27 MARCH 2025
Phase 3 includes faster, more comfortable and smoother security inspection with additional smart lanes capable of processing between 4,500 and 6,000 passengers an hour.
The new queuing management system is the first of its kind in Japan, automatically controlling flapper gates to switch waiting lines by utilizing real-time passenger flow data. The system enables passengers to be automatically guided to the security inspection lanes based on the number of passengers and their flow.
A new commercial area includes 13 stores across international departures, international arrivals and a street food court.
The project has already been recognised for its architectural vision as a finalist in the 2023 World Architecture Festival Awards for Future Projects – Infrastructure.
Originally designed by world renowned Italian architect Renzo Piano, the airport is considered an architectural icon. Regarded as part of the high-tech architecture movement of the 1990s, KIX’s industrial design is famous for its asymmetrical clear-span sweeping aerofoil roofline. At 1.7km long, it is one of the longest airport passenger terminal buildings in the world.
Principal Design Manager, Architect Jack Kato said the redesign had to respect the old while embracing new commercial opportunities for passengers.
“We broke away from the former gray color scheme, reinvigorating the interior spaces with a palette of natural materials to give the terminal a distinctly Japanese feel, but at the same time we opened up areas like the relocated immigration hall to provide an open space reflecting the original architecture and offering an inspiring arrival experience to start each journey,” Mr Kato said.
“This will transform the arrival experience of each journey into something inspirational.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331282189/en/
Contacts
Charlie Brooks
Charlie.brooks@populous.com
+44 7881268501
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom